ArticleCancers2026

KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase Trials.

Dilsa Mizrak Kaya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.